PMID- 31753244
OWN - NLM
STAT- MEDLINE
DCOM- 20210726
LR  - 20210726
IS  - 1557-8224 (Electronic)
IS  - 1089-3261 (Linking)
VI  - 24
IP  - 1
DP  - 2020 Feb
TI  - Genetic Predisposition to Drug-Induced Liver Injury.
PG  - 11-23
LID - S1089-3261(19)30053-4 [pii]
LID - 10.1016/j.cld.2019.08.003 [doi]
AB  - Identification of genetic predisposition to drug-induced liver injury (DILI) is 
      of paramount importance. Early candidate gene studies have identified various 
      polymorphisms in drug-metabolizing genes that infer increased DILI 
      susceptibility. Few of these have been confirmed in more recent genome-wide 
      association studies, which have identified several specific human leukocyte 
      antigen (HLA) alleles. The low incidence rate of DILI, however, leads to a low 
      positive predictive value for currently identified genetic variations, making 
      them unsuitable for pre-prescription screening. HLA screening incorporated into 
      clinical practice can aid the diagnostic process resulting in enhanced diagnostic 
      accuracy and confidence.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Stephens, Camilla
AU  - Stephens C
AD  - Unidad de Gestion Clinica de Aparato Digestivo, Instituto de Investigacion 
      Biomedica de Malaga-IBIMA, Hospital Universitario Virgen de la Victoria, 
      Universidad de Malaga, Boulevard Louis Pasteur 32, Malaga, 29071 Spain; Centro de 
      Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), 
      Spain.
FAU - Andrade, Raul J
AU  - Andrade RJ
AD  - Unidad de Gestion Clinica de Aparato Digestivo, Instituto de Investigacion 
      Biomedica de Malaga-IBIMA, Hospital Universitario Virgen de la Victoria, 
      Universidad de Malaga, Boulevard Louis Pasteur 32, Malaga, 29071 Spain; Centro de 
      Investigacion Biomedica en Red de Enfermedades Hepaticas y Digestivas (CIBERehd), 
      Spain. Electronic address: andrade@uma.es.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20191031
PL  - United States
TA  - Clin Liver Dis
JT  - Clinics in liver disease
JID - 9710002
RN  - 0 (HLA Antigens)
SB  - IM
MH  - *Chemical and Drug Induced Liver Injury/epidemiology/genetics
MH  - Genetic Predisposition to Disease
MH  - Genome-Wide Association Study
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Pharmacogenomic Testing/*methods
MH  - *Pharmacogenomic Variants
MH  - Predictive Value of Tests
OTO - NOTNLM
OT  - Candidate gene studies
OT  - Drug metabolism
OT  - Genome-wide association studies
OT  - Human leukocyte antigen
OT  - Pharmacogenetics
OT  - Pharmacogenomics
EDAT- 2019/11/23 06:00
MHDA- 2021/07/27 06:00
CRDT- 2019/11/23 06:00
PHST- 2019/11/23 06:00 [entrez]
PHST- 2019/11/23 06:00 [pubmed]
PHST- 2021/07/27 06:00 [medline]
AID - S1089-3261(19)30053-4 [pii]
AID - 10.1016/j.cld.2019.08.003 [doi]
PST - ppublish
SO  - Clin Liver Dis. 2020 Feb;24(1):11-23. doi: 10.1016/j.cld.2019.08.003. Epub 2019 
      Oct 31.